Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 7/20 | 0.52 |
| ▸ | ITGA4 | P13612 | 7/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | PHGDH | O43175 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2429977 | 0.92 | ITGB1 (0.50) | ITGB1ITGA4AKR1C3AKR1C2POLB | |
| SCHEMBL71415 | 0.89 | ITGB1 (0.60) | ITGB1ITGA4MAPTMAOB | |
| SCHEMBL5708295 | 0.89 | ITGB1 (0.49) | ITGB1ITGA4AKR1C3AKR1C2 | |
| SCHEMBL14491723 | 0.88 | ITGB1 (0.51) | ITGB1ITGA4POLBTP53MAPT | |
| SCHEMBL92363 | 0.84 | ITGB1 (0.42) | ITGB1ITGA4POLBNR4A2TP53 | |
| SCHEMBL14591769 | 0.82 | ITGB1 (0.47) | ITGB1ITGA4POLBTP53MAPT | |
| SCHEMBL2432198 | 0.82 | ITGB1 (0.48) | ITGB1ITGA4POLBTP53MAPT | |
| SCHEMBL91539 | 0.81 | MAPT (0.42) | ITGB1ITGA4POLBNR4A2TP53 | |
| SCHEMBL2433507 | 0.81 | ITGB1 (0.41) | ITGB1ITGA4POLBNR4A2TP53 | |
| SCHEMBL14491702 | 0.80 | ITGB1 (0.49) | ITGB1ITGA4POLBTP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1346982-B1 | VLA-4 INHIBITORS | DAIICHI SEIYAKU CO (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-20070149606-A1 | Process for producing phenylacetic acid derivative | DAIICHI PHARMACEUTICAL CO.,LTD. (JP) | 2007-06-28 | — | — | US | disclosed |
| US-20070149606-A1 | Process for producing phenylacetic acid derivative | DAIICHI PHARMACEUTICAL CO.,LTD. (JP) | 2007-06-28 | — | — | US | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| EP-1698611-A1 | PROCESS FOR PRODUCING PHENYLACETIC ACID DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
| US-20040110945-A1 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
| EP-1346982-A1 | VLA-4 INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110945-A1 | Vla-4 inhibitors | VCAM1, ITGA1, ITGB4 | ITGB1 5/4885ITGA4 4/4885AKR1C3 1549/4885 |
| US-20070149606-A1 | Process for producing phenylacetic acid derivative | UGT1A4, VPS4B, CYP3A4 | ITGB1 1987/4885ITGA4 106/4885AKR1C3 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.